These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36642706)

  • 1. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer.
    Wang Z; Zhang J; Dai F; Li B; Cheng Y
    J Ovarian Res; 2023 Jan; 16(1):12. PubMed ID: 36642706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
    Shen L; Li A; Cui J; Liu H; Zhang S
    J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
    Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
    Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of NK Marker Genes in Ovarian Cancer by scRNA-seq Combined with WGCNA Algorithm.
    He X; Feng W
    Mediators Inflamm; 2023; 2023():6845701. PubMed ID: 37144238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
    You Y; Yang Q
    BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating scRNA-seq and bulk RNA-seq to characterize infiltrating cells in the colorectal cancer tumor microenvironment and construct molecular risk models.
    Wang Q; Zhang YF; Li CL; Wang Y; Wu L; Wang XR; Huang T; Liu GL; Chen X; Yu Q; He PF
    Aging (Albany NY); 2023 Dec; 15(23):13799-13821. PubMed ID: 38054820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel lipid metabolism-related gene signature to predict outcomes and the tumor immune microenvironment in gastric cancer by integrated analysis of single-cell and bulk RNA sequencing.
    Zhang J; Wang H; Tian Y; Li T; Zhang W; Ma L; Chen X; Wei Y
    Lipids Health Dis; 2023 Dec; 22(1):212. PubMed ID: 38042786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Hua T; Liu DX; Zhang XC; Li ST; Wu JL; Zhao Q; Chen SB
    Eur J Med Res; 2024 Jul; 29(1):358. PubMed ID: 38970067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer-specific dysregulated genes with prognostic significance: scRNA-Seq with bulk RNA-Seq data and experimental validation.
    Liu C; Zhang Y; Li X; Wang D
    Ann N Y Acad Sci; 2022 Jun; 1512(1):154-173. PubMed ID: 35247207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
    Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
    Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
    Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
    Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer.
    Pei S; Zhang P; Chen H; Zhao S; Dai Y; Yang L; Kang Y; Zheng M; Xia Y; Xie H
    Front Endocrinol (Lausanne); 2023; 14():1135297. PubMed ID: 36843602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
    Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting nucleotide metabolic pathways in colorectal cancer by integrating scRNA-seq, spatial transcriptome, and bulk RNA-seq data.
    Zhao S; Zhang P; Niu S; Xie J; Liu Y; Liu Y; Zhao N; Cheng C; Lu P
    Funct Integr Genomics; 2024 Apr; 24(2):72. PubMed ID: 38594466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model.
    Liang L; Yu J; Li J; Li N; Liu J; Xiu L; Zeng J; Wang T; Wu L
    Front Oncol; 2021; 11():711020. PubMed ID: 34621670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
    Zheng P; Li N; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
    Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
    Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
    Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
    Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.